Investor Overview

NASDAQ: XBIT0.134.95Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News
06/09/17XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim AnalysisPrinter Friendly Version
06/01/17XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO MeetingPrinter Friendly Version
05/30/17Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal CancerPrinter Friendly Version

Read more »

Upcoming Events

There are currently no events scheduled.

Read more »